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Background and Purpose
Current definitions of drug resistance are shaped by the 
pharmacotherapeutic fields they occurred in. They usually 
mention various contributing factors and refer either to the 
clinical or the biomarker level. Particular attention has been 
attracted by antiplatelet resistance, a phenomenon with 
clinical, cellular and pharmacogenetical contributors. However, 
the impact of every single factor to antiplatelet resistance 
in outpatients under prescribed antiplatelet therapy has 
not been comprehensively evaluated so far, neither has the 
temporal pattern of drug intake been studied as a possible 
contributor.
Methods
We propose generally applicable definitions of drug resistance, 
therapy failure and a classification of contributing factors to 
drug resistance. We introduce a study design with the use 
of blisterpacks in a target population (i.e. patients with a 
prescription of antiplatelet drugs), filled with the entire oral 
medication regimen, and equipped with electronic multidrug 
compliance monitoring (e-MCM) allowing thus to evaluate in 
a stepwise way the impact of the contributing factors (e.g. 
potential drug-drug interactions, genetic polymorphism) on 
biomarker outcome (i.e. in vitro platelet aggregation), with 
proven intake of the polytherapy.
Discussion and conclusion
Drug resistance should be judged with the knowledge of 
the contributing factors and in the context of a patient’s 
polytherapy under daily life conditions. The use of electronic 
multidrug compliance monitoring (e-MCM) allows the ruling 
out of non-compliance and the evaluation of the impact 
of potential drug-drug interactions on biomarker outcome. 
Pharmacogenetic testing may thus be restricted to those 
patients with a persistent lack of response, and the impact 
of the genotype may be interpreted within patients’ specific 
clinical context. An evidence-based optimisation of the 
therapy in case of insufficient biomarker response may thus 
be given, and the intervention can be stratified according to 
the identified contributing factors. The debate may then be 
opened on the clinical benefit and the cost-effectiveness of 
practices currently used to overcome insufficient effectiveness 
solely based on biomarker findings.
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Background
The term “drug resistance” has emerged from antibiotic 
and anticancer therapy and has been discussed in many 
fields of pharmacotherapy, such as antihypertensive drugs1, 
antiepileptics2,3, antidepressants4, lipid modifying therapy5 
and antiplatelet medication6-8. 
“Drug resistance” was introduced as a Medical Subject 
Heading (MeSH) in 1972 and refers to a “diminished or failed 
response of an organism, disease or tissue to the intended 
effectiveness of a chemical or drug”. This circumscription 
provides a short and global definition of the phenomenon, but 
does not specify the clinical context under which resistance is 
observed. Furthermore, the definition omits to mention if the 
effectiveness is measured on a clinical level (e.g. mortality) or 
on the surrogate marker level.
The term “drug resistance” has further been shaped 
by various authors in the context of their specific field of 
interest. The different proposed definitions have some 
basic features in common, like the clinical relevance of drug 
resistance, its multifactorial aspect, and its detection through 
pharmacological biomarkers1-8, but no generally accepted 
concept of drug resistance has emerged.
Antiplatelet Drug therapy for the Investigation of Drug 
Resistance
Dual antiplatelet therapy with aspirin and clopidogrel is a well-
established regimen in the prevention of stent thrombosis9, 
whereas aspirin has proved its efficacy in the primary and 
secondary prevention of cardiovascular and cerebrovascular 
events10. Up to 20% of patients experience recurrent 
cardiovascular events despite dual antiplatelet therapy after 
percutaneous coronary intervention11. These incidence rates 
have raised the question of antiplatelet drug resistance, which 
is characterised by persistent in vitro platelet aggregation. 
The term “antiplatelet resistance” describes “a phenomenon 
of measureable, persistent platelet activation that occurs 
in patients with prescribed therapeutic doses of aspirin”12. 
This definition is restricted to a biochemical phenomenon 
and includes any factor liable to compromise the biomarker 
outcome, including clinical factors that reduce drug exposure 
like non-compliance or poor absorption. 
Clopidogrel resistance received special attention and was 
differently named “nonresponsiveness”13 or “variability in 
platelet response”14. The phenomenon has been associated 
with CYP2C19 loss-of-function genotype15 and with drug-
drug interactions affecting CYP2C19 and CYP3A4 metabolic 
capacity16-18. Further factors with possible influence on platelet 
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activity were described, like tobacco smoking19, diabetes 
mellitus20 and systemic inflammation with increased platelet 
turnover21. None of these factors emerged as the most likely 
cause for the unmet clinical outcome, but their effects on in 
vitro platelet aggregation are evident. 
Non-compliance must be generally suspected when patients 
under antiplatelet therapy do not display the expected in vitro 
platelet inhibition. Non-compliance has been described as a 
contributor of outstanding impact in aspirin therapy22, with a 
prevalence of 22% in a cohort with manifest coronary artery 
disease and stroke23. However, when aggregation is inhibited, 
this means that an appropriate amount of the prescribed 
drug has been taken to produce the pharmacological effect, 
not that the prescribed regimen has been adhered to24. The 
contribution of non-compliant behaviour to antiplatelet 
resistance in outpatients under prescribed antiplatelet therapy 
has not been evaluated so far.
Definition of and contributing Factors to Drug Resistance
“The absence of the expected biomarker response under 
(adequately) prescribed therapy (in correctly diagnosed 
patients)” may represent the cornerstone of a general 
definition of drug resistance. Consequently, we support 
that an unfavourable clinical outcome should be addressed 
as “treatment failure”25 while “drug resistance” should be 
reserved for therapies whose efficacy can be evaluated with 
pharmacological biomarkers.
When a patient fails to respond adequately to a prescribed 
treatment, either on a clinical or on a biomarker level, 
the physician must distinguish among different causes of 
variability (pharmacological, behavioural, biological). Often, 
a combination of factors has produced the suboptimal 
results. Given the above definition of drug resistance, the 
contributing factors can be classified into clinical, genetic and 
cellular factors (Table 1), as already proposed for antiplatelet 
resistance26. Each single factor may negatively influence the 
biomarker response, and the ensuing impact depends on the 
taken drug.
In summary, we promote the comprehensive assessment 
of drug resistance with the evaluation of all contributing 
factors. To this purpose, we propose a study design with the 
implementation of a new compliance monitoring technology, 
using the field of antiplatelet resistance as a model.
Aims of the Study
The aims of the study of which the design is presented in 
this article are to identify resistance to antiplatelet therapy 
in outpatients with a prescription of antiplatelet agents, and 
to assess all factors that compromise the biomarker response, 
i.e. the platelet aggregation. 
Methods
Blisterpack and compliance Measurement technology
We chose a commercially available weekly blisterpack with 
7x4 compartments (Pharmis GmbH, Beinwil a.S., Switzerland), 
filled with the entire oral medication regimen of the patient 
(Rx and OTC drugs). The back of the blisterpack is covered 
with a clear, self-adhering polymer foil (provided by ECCT B.V. 
Eindhoven, NL) with loops of conductive wires and connected 
to electronic components (Fig. 1). The attached microchip 
measures the electrical resistance, and records the time of its 
changes when a loop is broken, i.e. when a cavity is emptied. 
The data is transferred with a wireless communication device 
(near field communication) to a web-based database. 
This electronic multidrug compliance monitoring (e-MCM) 
system enables the monitoring of the entire pharmacotherapy, 
and thus assessment of compliance behaviour and drug-drug 
interactions.
Recruitment and Inclusion criteria
Patients are recruited at their local general practitioners (GP) 
surgeries during a routine consultation. Inclusion criteria 
are the prescription for aspirin and/or clopidogrel for the 
prevention of primary or secondary atherothrombotic events 
(cardiovascular, stent thrombosis or cerebrovascular event), 
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Table 1: Contributing factors to drug resistance, with specific examples for 
antiplatelet drug resistance
Factors contributing to drug resistance 
Clinical factors
Prescription
Patient non-compliance
Poor absorbance
Drug-drug interactions
Lifestyle factors
Comorbidity
Genetic factors
Pharmacokinetic
Pharmacodynamic
Cellular factors
Cell turnover
Adaptive cellular mechanisms
Up-/down-regulation of cell 
metabolism
Factors contributing to antiplatelet drug 
resistance (aspirin and/or clopidogrel)25, 26
Failure to prescribe; Underdosing
Mostly delayed or omitted doses
Interaction with ibuprofene (aspirin); 
Interaction with PPIs and statins 
(clopidogrel)
Tobacco smoking; Elevated body mass index
Diabetes mellitus;
Acute coronary syndrome;
Systemic inflammation
Polymorphisms of MDR1 and CYP 
isoforms
Polymorphisms of P2Y12 and GPIIb/IIIa 
Increased platelet turnover
Increased ADP exposure
Up-regulation of ADP-mediated pathways
or for the treatment of peripheral 
arterial occlusive disease (PAOD), 
and the patient’s agreement to get 
a weekly blisterpack with electronics 
(e-MCM) prefilled with all orally 
administered drugs and to leave 
all extra drugs at the study centre. 
Exclusion criteria are acute cardiac 
symptoms, residence in a care home 
or receiving home care, and lack 
of discernment to manage one’s 
own pharmacotherapy. The use of 
a pill organiser is not an exclusion 
criterion.
Biomarkers for Antiplatelet 
therapy
Historically, platelet aggregation in 
platelet-rich plasma was the method 
of choice to assess in vitro platelet 
activity27. In recent years, new 
assays have become commercially 
available. Raising evidence supports 
the introduction of multiple 
electrode aggregometry (MEA, 
Dynabyte, Munich, Germany) for the measurement of platelet 
aggregation and the prediction of the clinical outcome28. In 
the described study design, MEA is applied to measure in vitro 
platelet aggregation. The MEA instrument allows two ways to 
express the AUC: as arbitrary aggregation units (AU · min) or 
as units (U), whereas 10 AU · min correspond to 1 U. The cut-
off value was set at 54 U29.
Study Plan and Stepwise Assessment of contributing 
Factors
At visit 1, demographic data including smoking status, 
educational level and social background is collected; 
baseline laboratory data including platelet aggregation is 
measured, and the individualised blisterpack for one week is 
delivered. Patients are informed that their drug intake will be 
electronically monitored, and advised to take their drugs as 
they were instructed in usual care. Patients’ extra drugs are 
stored at the study centre during participation, thus rendering 
parallel drug consumption impossible.
At visit 2, one week later, in vitro platelet aggregation 
is measured and serves to dichotomise the study cohort 
into subjects with a) sufficient and b) insufficient platelet 
inhibition. The latter group will get another week of 
compliance-monitored therapy, with an additional direct 
observation (DOT, directly observed therapy) of the doses 
containing the antiplatelet drug on five of seven days. 
The assessment of drug-drug interactions and 
pharmacogenetic polymorphisms is performed in all patients.
Sample Size Estimation
The incidence of antiplatelet resistance in patients with 
a prescription for aspirin and/or clopidogrel varies widely 
(8 - 45%)12. For circumstances as defined in our study, an 
incidence of 20-30% seems reasonable. The presence of main 
contributing factors in the general population is assumed to 
be 15% for the loss-of-function genotype (g), 60% for drug-
drug interactions (d), and 20% for comorbidities (c). Thus, 
the codes of the different patient groups and the rates of 
non-responders would be g0d0c0 (2%), g0d0c1 (60%), 
g0d1c0 (15%), g0d1c1 (65%), g1d0c0 (55%), g1d0c1 
(75%), g1d1c0 (75%), g1d1c1 (90%), with 1 if the factor 
is present, and 0 if the factor is absent. The primary analysis 
should demonstrate that the main contributing factors have 
the expected influence on non-response. A Monte Carlo 
simulation with adjusted sampling for the estimated overall 
incidence of non-response resulted in a required total of 493 
evaluable patients to achieve a power of 80% as for the 
primary analysis.
Expected Results
Baseline platelet aggregation at visit 1 mirrors the 
effectiveness of a patient’s polytherapy, i.e. drug efficacy 
under daily life conditions. We expect the values after one 
week to show an improved platelet inhibition, independently 
of the baseline value (and very likely because of the 
Hawthorne effect), and to draw conclusions on the optimal 
temporal pattern of drug intake on biomarker outcome with 
antiplatelet drugs.
With proven compliance by means of e-MCM, we will be 
able to quantify the clinical, genetic and cellular factors other 
than non-compliance in patients with insufficient platelet 
inhibition under aspirin and/or clopidogrel. With the tracking 
of the entire pharmacotherapy, we will be able to evaluate the 
impact of drug-drug interaction on the biomarker response, 
and to make recommendations for action when platelet 
inhibition is insufficient. We expect differences between 
both groups (aspirin and clopidogrel) in frequency rates, with 
a greater importance of pharmacogenetic polymorphisms 
and drug-drug interactions under clopidogrel therapy. Non-
compliance is assumed to have a similar impact on in vitro 
platelet inhibition for both antiplatelet drugs. 
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Figure 1
Discussion and conclusion
The use of electronic multidrug compliance monitoring 
(e-MCM) for the assessment of drug resistance allows us 
to rule out non-compliance and to evaluate the impact of 
potential drug-drug interactions on biomarker outcome. 
Pharmacogenetic testing may be restricted to those 
patients with a persistent lack of response. An evidence-
based optimisation of the therapy in case of insufficient 
biomarker response is thus given, and the intervention can be 
stratified according to the identified contributing factors. The 
efficacy of the intervention can then be estimated with the 
biomarker outcome. In essence, the switch to another drug 
can be proposed only in case of proven inefficacy (genetic 
polymorphism, comorbidity, inevitable interaction). Our 
stepwise approach to identify and assess drug resistance in 
individual patients is applicable to many therapeutic settings, 
like treatment of dyslipidemia, hypertension, osteoporosis, 
and congestive heart failure.
To our knowledge, prospective compliance monitoring 
in patients with antiplatelet drug resistance has not been 
evaluated so far; neither has the applicability of in vitro 
platelet monitoring with multiple electrode aggregation 
(MEA) in a primary care setting. Insufficiently lowered platelet 
aggregation with MEA is associated with an unfavourable 
clinical outcome and thus underlines the relevance of the 
finding. Stratified interventions may optimise safety and 
effectiveness of drug therapies under daily life conditions, and 
back up the utility of diagnostic strategies addressing drug 
resistance. Further studies are needed to evaluate the clinical 
benefit and cost-effectiveness of identifying and treating 
drug resistance in different population groups.
Summary Points
•  We support a new definition of drug resistance and propose 
its attribution to an inadequate biomarker response to 
prescribed drugs.
•  Drug resistance is a phenomenon with multiple contributing 
factors on the clinical, genetic and cellular level.
•  Antiplatelet drug resistance can serve as a model for drug 
resistance.
•  The assessment of contributing factors must involve 
electronic multidrug compliance monitoring (e-MCM) to 
rule out non-compliance and to measure exposure to drug-
drug interactions.
•  More studies are needed to evaluate the clinical benefit 
and cost-effectiveness of identifying and treating drug 
resistance in different population groups.
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